{"id":99223,"date":"2019-05-05T00:00:50","date_gmt":"2019-05-17T08:20:09","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/99223\/"},"modified":"2019-05-17T16:20:10","modified_gmt":"2019-05-17T08:20:10","slug":"3ad4ab4031","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/99223\/","title":{"rendered":"\u80bf\u7624\u5feb\u62a5 | \u65b0\u6297\u4f53\u5076\u8054\u836f\u7269\u6cbb\u7597\u4e73\u817a\u764c"},"content":{"rendered":"
\n

\"\u80bf\u7624\u5feb\u62a5
<\/p>\n

\u80bf\u7624\u65f6\u95f4\u8fd1\u671f\u5feb\u62a5\uff0c\u5e26\u7ed9\u4f60\u6700\u65b0\u7684\u8d44\u8baf\u3002<\/p>\n


<\/p>\n

\n
\n
\n
\n

\u9776\u5411\u9aa8\u9ad3\u7624\uff0cCAR T \u663e\u795e\u529b<\/span><\/strong><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u4e34\u5e8a\u524d\u7814\u7a76\u663e\u793a\u4e00\u79cd\u9776\u5411B\u7ec6\u80de\u6210\u719f\u6297\u539f\uff08BCMA\uff09\u7684 CAR T \u7ec6\u80de\u7597\u6cd5 bb2121 \u5728\u6cbb\u7597\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u4e2d\u5177\u6709\u6f5c\u529b\u30025 \u6708 2 \u65e5\uff0cbb2121 \u6cbb\u7597\u590d\u53d1\u96be\u6cbb MM \u7684 1 \u671f\u7814\u7a76\u7ed3\u679c\u516c\u5e03\uff0c\u5728\u7ebf\u53d1\u8868\u5728 NEJM \u4e0a[1]<\/span><\/sup>\u3002<\/p>\n


<\/p>\n

\u5171\u62a5\u9053 33 \u540d\u60a3\u8005\u6570\u636e\u3002\u8840\u6db2\u5b66\u6bd2\u6027\u662f\u6700\u5e38\u89c1\u7684 3 \u7ea7\u4ee5\u4e0a\u4e0d\u826f\u4e8b\u4ef6\uff0c\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\u53d1\u751f\u7387 76%\uff0c\u795e\u7ecf\u6bd2\u6027 42%\uff0c\u4f46 3 \u7ea7\u4ee5\u4e0a\u53d1\u751f\u7387\u4e0d\u9ad8\u3002ORR \u8fbe\u5230 85%\uff0c\u5305\u62ec 45%\u7684 CR \u7387\uff0c\u8bc1\u5b9e BCMA \u5bfc\u5411\u7684\u7ec6\u80de\u514d\u75ab\u5177\u6709\u6297\u80bf\u7624\u6d3b\u6027\u3002<\/p>\n


<\/p>\n

\n

1 \u671f\u7814\u7a76\u7684\u5242\u91cf\u9012\u589e\u9636\u6bb5\u4f7f\u7528 bb2121 \u5355\u836f\u5242\u91cf50<\/span>\u00d7<\/span>106<\/sup>,150<\/span>\u00d7<\/span>106<\/sup>\uff0c<\/span>\u6216 800<\/span>\u00d7<\/span>106<\/sup><\/span>\u4e2a CAR+T \u7ec6\u80de\uff0c\u6269\u5c55\u9636\u6bb5\u4f7f\u7528 150<\/span>\u00d7<\/span>106 <\/sup><\/span>\u5230 <\/span>450<\/span>\u00d7<\/span>106 <\/sup><\/span>\u4e2aCAR+T \u7ec6\u80de\u3002\u60a3\u8005\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e09\u7ebf\u6cbb\u7597\uff0c\u5305\u62ec\u86cb\u767d\u9176\u6291\u5236\u5242\u548c\u514d\u75ab\u8c03\u8282\u836f\u7269\uff0c\u4e14\u4e24\u7c7b\u836f\u7269\u90fd\u96be\u6cbb\u3002\u9996\u8981\u7814\u7a76\u7ec8\u70b9\u662f\u5b89\u5168\u6027\u3002<\/span><\/span><\/p>\n


<\/span><\/p>\n

\u62a5\u9053\u6700\u521d\u63a5\u53d7 bb2121 \u6cbb\u7597\u7684 33 \u540d\u60a3\u8005\u3002\u8840\u6db2\u5b66\u6bd2\u6027\u662f\u6700\u5e38\u89c1\u7684 3 \u7ea7\u4ee5\u4e0a\u4e0d\u826f\u4e8b\u4ef6\uff0c\u5305\u62ec\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0885%\uff09\uff0c\u767d\u7ec6\u80de\u51cf\u5c11\uff0858%\uff09\uff0c\u8d2b\u8840\uff0845%\uff09\u548c\u8840\u5c0f\u677f\u51cf\u5c11\uff0845%\uff09\u300225 \u540d\u60a3\u8005\uff0876%\uff09\u53d1\u751f\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\uff0c2 \u540d\uff086%\uff09\u4e3a 3 \u7ea7\u3002\u795e\u7ecf\u6bd2\u6027 42%\uff0c1 \u540d\uff083%\uff09\u53d1\u751f\u53ef\u9006\u7684 4 \u7ea7\u795e\u7ecf\u6bd2\u6027\u3002<\/span><\/p>\n


<\/span><\/p>\n

ORR 85%\uff0c\u5305\u62ec 15 \u540d\uff0845%\uff09CR\u30026\/15 \u540d CR \u60a3\u8005\u590d\u53d1\u3002\u4e2d\u4f4d PFS 11.8 \u4e2a\u6708\u3002\u53ef\u8bc4\u4f30\u6700\u5c0f\u6b8b\u7559\u75c5\u7076\uff08MRD\uff09\u7684 16 \u540d\u53cd\u5e94\u60a3\u8005\u90fd\u51fa\u73b0 MRD \u9634\u6027\u72b6\u6001\uff08\u226410-4\u6709\u6838\u7ec6\u80de\uff09\u3002CAR T \u7ec6\u80de\u6269\u589e\u548c\u53cd\u5e94\u76f8\u5173\uff0cCAR T \u7ec6\u80de\u8f93\u6ce8\u540e\u53ef\u6301\u7eed 1 \u5e74\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u65b0\u7ec4\u5408\u653b\u514b\u970d\u5947\u91d1\u6dcb\u5df4\u7624<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u6297 PD-1 \u836f\u7269\u5728\u590d\u53d1\/\u96be\u6cbb\u7ecf\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08cHL\uff09\u4e2d\u53ef\u4ee5\u53d6\u5f97\u5f88\u9ad8\u7684\u53cd\u5e94\u7387\uff0c\u800c\u5730\u897f\u4ed6\u6ee8\u53ef\u4ee5\u63d0\u9ad8 T \u7ec6\u80de\u529f\u80fd\uff0c\u6709\u53ef\u80fd\u8fdb\u4e00\u6b65\u63d0\u9ad8\u514d\u75ab\u6cbb\u7597\u7597\u6548\u30024 \u6708 30 \u65e5\uff0cJCO \u53d1\u8868\u7814\u7a76\u8bc4\u4f30\u4e86\u8fd9\u4e00\u7ec4\u5408\u6cbb\u7597\u590d\u53d1\u96be\u6cbb cHL \u7684\u7597\u6548\u548c\u5b89\u5168\u6027[2]<\/span><\/sup>\u3002<\/p>\n


<\/p>\n

\u7814\u7a76\u53d1\u73b0\u672a\u63a5\u53d7\u8fc7\u6297 PD-1 \u6cbb\u7597\u7684\u60a3\u8005\uff0c\u8054\u5408\u6cbb\u7597\u7684 CR \u7387\u663e\u8457\u63d0\u9ad8\uff0c\u4e14\u8054\u5408\u6cbb\u7597\u7684\u4e0d\u826f\u53cd\u5e94\u8f7b\u5fae\u3002\u5730\u897f\u4ed6\u6ee8+\u5361\u745e\u5229\u73e0\u5355\u6297\u662f\u9006\u8f6c\u590d\u53d1\/\u96be\u6cbb cHL \u60a3\u8005\u5bf9\u4e8e PD-1 \u6291\u5236\u5242\u8010\u836f\u6027\u7684\u65b0\u7597\u6cd5\u3002<\/p>\n


<\/p>\n

\n

\u7814\u7a76\u7eb3\u5165\u63a5\u53d7\u8fc7\u81f3\u5c11\u4e24\u7ebf\u6cbb\u7597\u3001\u672a\u63a5\u53d7\u8fc7\u6297 <\/span>PD-1 <\/span>\u6cbb\u7597\u7684\u590d\u53d1<\/span>\/<\/span>\u96be\u6cbb <\/span>cHL <\/span>\u60a3\u8005\uff0c\u968f\u673a\uff08<\/span>1:2<\/span>\uff09\u63a5\u53d7\u5361\u745e\u5229\u73e0\u5355\u6297 <\/span>200 mg <\/span>\u6216\u5730\u897f\u4ed6\u6ee8 <\/span>10 mg\/d d1-5+<\/span>\u5361\u745e\u5229\u73e0\u5355\u6297 <\/span>200 mg d8 Q3W <\/span>\u6cbb\u7597\u3002\u4e4b\u524d\u63a5\u53d7\u8fc7\u6297 <\/span>PD-1 <\/span>\u6cbb\u7597\u7684\u60a3\u8005\u5206\u914d\u5230\u8054\u5408\u7ec4\u3002\u9996\u8981\u7814\u7a76\u7ec8\u70b9\u662f <\/span>CR <\/span>\u7387\u548c\u5b89\u5168\u6027\u3002<\/span><\/span><\/p>\n


<\/span><\/p>\n

\u5171\u5165\u7ec4 86 \u540d\u60a3\u8005\u3002\u4e2d\u4f4d\u968f\u8bbf 14.9 \u4e2a\u6708\uff0c\u672a\u63a5\u53d7\u8fc7\u6297 PD-1 \u6cbb\u7597\u7684\u60a3\u8005\uff0c\u5355\u836f\u7ec4\u548c\u8054\u5408\u7ec4\u7684 CR \u7387\u5206\u522b\u662f 32%\uff086\/19\uff09vs 71%\uff0830\/42\uff09\uff08P=0.003\uff09\u3002\u622a\u6b62\u6570\u636e\u5206\u6790\u65f6\uff0c6 \u4e2a\u6708\u7684\u53cd\u5e94\u6301\u7eed\u7387\u662f 76% vs 100%\u3002<\/span><\/p>\n

\u4e4b\u524d\u63a5\u53d7\u8fc7\u6297 PD-1 \u6cbb\u7597\u7684\u60a3\u8005\u4e2d\uff0cCR \u7387\u662f 28%\uff0cPR \u7387\u662f 24%\u300210 \u540d\u60a3\u8005\u5728 6 \u4e2a\u6708\u7684\u65f6\u5019\u53cd\u5e94\u6301\u7eed\uff0c81%\u7684\u53cd\u5e94\u8005 DoR \u63a8\u6d4b\u8d85\u8fc7 1 \u5e74\u3002<\/span><\/p>\n

\u4e24\u7ec4\u6700\u5e38\u89c1\u7684\u4e0d\u826f\u4e8b\u4ef6\u4e3a\u65e0\u4e34\u5e8a\u610f\u4e49\u7684\u6a31\u6843\u72b6\u8840\u7ba1\u7624\u548c\u81ea\u9650\u6027\u7684\u767d\u7ec6\u80de\u51cf\u5c11\u3002<\/span>
<\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u75c5\u6bd2\u9884\u6d4b\u5934\u9888\u90e8\u9cde\u764c\u590d\u53d1<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u53e3\u8154 HPV \u75c5\u6bd2 DNA \u6301\u7eed\u9633\u6027\u53ef\u80fd\u4e0e HPV \u9633\u6027\u5934\u9888\u90e8\u9cde\u764c\uff08HNSCC\uff09\u7684\u590d\u53d1\u76f8\u5173\u30025 \u6708 2 \u65e5\uff0cJAMA Oncol \u53d1\u8868\u7814\u7a76\uff0c\u8bc4\u4f30\u4e86\u53e3\u8154\u53ca\u53e3\u54bd\u9cde\u764c\u60a3\u8005\u4e2d HPV DNA \u52a8\u6001\u68c0\u6d4b\u548c\u75be\u75c5\u7ed3\u5c40\u7684\u5173\u7cfb[3]<\/sup>\u3002<\/span><\/p>\n


<\/p>\n

\u6cbb\u7597\u540e\u80bf\u7624\u578b HPV DNA \u68c0\u51fa\u7387\u548c\u8f7d\u91cf\u51fa\u73b0\u5feb\u901f\u4e0b\u964d\uff0c\u800c\u75c5\u6bd2\u7684\u6301\u7eed\u68c0\u51fa\u548c\u590d\u53d1\u53ca\u6b7b\u4ea1\u98ce\u9669\u76f8\u5173\u3002\u80bf\u7624\u578b HPV DNA \u53ef\u80fd\u662f HNSCC \u6cbb\u7597\u53cd\u5e94\u548c\u8fdb\u5c55\u98ce\u9669\u7684\u5206\u5b50\u6807\u5fd7\u7269\u3002<\/p>\n


<\/span><\/p>\n

\n

\u7eb3\u5165 <\/span>396 <\/span>\u540d\u65b0\u8bca\u65ad\u53e3\u8154\u6216\u53e3\u54bd <\/span>HNSCC <\/span>\u7684\u60a3\u8005\uff0c\u6536\u96c6\u8bca\u65ad\u65f6\u548c\u521d\u6b21\u6cbb\u7597\u7ed3\u675f\u7684\u53e3\u8154\u6f31\u6db2\u6807\u672c\u3002\u8bc4\u4ef7\u6cbb\u7597\u524d\u3001\u4e2d\u3001\u540e\u7684 <\/span>HPV DNA <\/span>\u60c5\u51b5\u3002\u8bc4\u4f30\u80bf\u7624\u578b\u548c\u975e\u80bf\u7624\u578b\u53e3\u8154 <\/span>HPV DNA <\/span>\u68c0\u6d4b\u548c <\/span>RFS <\/span>\u4ee5\u53ca <\/span>OS <\/span>\u7684\u5173\u7cfb\u3002<\/span><\/p>\n


<\/span><\/p>\n

396 \u540d\u60a3\u8005\u4e2d\uff0cHPV \u9633\u6027 HNSCC \u60a3\u8005\u5177\u6709\u66f4\u9ad8\u7684 HPV \u68c0\u51fa\u7387\uff0884.2% vs 12.4%\uff0cP\uff1c0.001\uff09\u3002<\/span><\/p>\n

\u521d\u59cb\u6cbb\u7597\u540e\uff0c\u80bf\u7624\u578b HPV \u7684\u68c0\u51fa\u7387\u548c\u8f7d\u91cf\u663e\u8457\u4e0b\u964d\uff0c\u8bca\u65ad\u540e\u6bcf\u589e\u52a0\u4e00\u4e2a\u6708\uff0c\u75c5\u6bd2\u68c0\u51fa\u7684\u53ef\u80fd\u6027 OR \u4e3a 0.41\uff0c\u800c\u975e\u80bf\u7624\u578b\u4e0d\u4e0b\u964d\uff08OR 1.01\uff09\u3002\u5438\u70df\u548c\u80bf\u7624\u578b HPV DNA \u6e05\u9664\u4e0b\u964d\u76f8\u5173\uff08HR 0.54\uff09\u3002<\/span>
<\/p>\n

HPV \u9633\u6027\u60a3\u8005\u4e2d\uff0c\u548c\u6cbb\u7597\u540e\u68c0\u6d4b\u4e0d\u5230\u80bf\u7624\u578b DNA \u7684\u60a3\u8005\u76f8\u6bd4\uff0c\u6cbb\u7597\u540e\u6301\u7eed\u68c0\u6d4b\u5230\u80bf\u7624\u578b HPV \u60a3\u8005\u7684 2 \u5e74 OS \u7387\u663e\u8457\u66f4\u4f4e\uff0868% vs 95%\uff0cHR 6.61\uff0cP=0.003\uff09\uff0cRFS \u4e5f\u66f4\u4f4e\uff0855% vs 88%\uff0cHR 3.72\uff0cP\uff1c0.001\uff09\u3002\u975e\u80bf\u7624\u578b HPV DNA \u5219\u548c\u7ed3\u5c40\u4e0d\u76f8\u5173\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u65b0\u6297\u4f53\u5076\u8054\u836f\u7269\u6cbb\u7597\u4e73\u817a\u764c<\/span><\/strong><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

Lancet Oncol \u4e8e 4 \u6708 29 \u65e5\u5728\u7ebf\u53d1\u8868 Trastuzumab deruxtecan DS-8201a\uff09\u2014\u2014\u4e00\u79cd\u65b0\u7684 HER2 \u6297\u4f53\u5076\u8054\u62d3\u6251\u5f02\u6784\u9176 1 \u6291\u5236\u5242\u836f\u7269\u6cbb\u7597\u63a5\u53d7\u8fc7 T-DM1 \u6cbb\u7597\u7684\u8fdb\u5c55\u671f HER2 \u9633\u6027\u4e73\u817a\u764c\u7684\u5242\u91cf\u6269\u589e 1 \u671f\u7814\u7a76\u7ed3\u679c[4]<\/span><\/sup>\u3002<\/p>\n


<\/p>\n

3 \u7ea7\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u4e3b\u8981\u4e3a\u8840\u6db2\u5b66\u6bd2\u6027\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u3002\u5728\u63a5\u53d7\u8fc7 T-DM1 \u6cbb\u7597\u7684\u60a3\u8005\u4e2d\uff0cORR \u4f9d\u65e7\u8fbe\u5230 59.5%\uff0c\u521d\u6b65\u663e\u793a\u51fa\u6d3b\u6027\u3002<\/p>\n


<\/span><\/p>\n

\n

\u836f\u7269\u7684\u6700\u7ec8\u63a8\u8350\u5242\u91cf\u662f 5.4 mg\/kg \u6216 6.4 mg\/kg\uff0c\u5171 115 \u540d\u60a3\u8005\u63a5\u53d7\u6cbb\u7597\u3002<\/span><\/p>\n

3 \u7ea7\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u5305\u62ec\u8d2b\u8840\uff0817%\uff09\uff0c\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0814%\uff09\uff0c\u767d\u7ec6\u80de\u51cf\u5c11\uff089%\uff09\u548c\u8840\u5c0f\u677f\u51cf\u5c11\uff088%\uff09\u3002<\/span>\u4e25\u91cd\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u53d1\u751f\u7387 19%\u3002<\/span>
<\/p>\n

\u7814\u7a76\u8005\u6c47\u62a5 20 \u4f8b\u95f4\u8d28\u6027\u80ba\u75c5\uff0c\u80ba\u708e\u6216\u673a\u5316\u6027\u80ba\u708e\uff0c\u5305\u62ec 1 \u4f8b 3 \u7ea7\u4e8b\u4ef6\u548c 2 \u4f8b\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\u3002<\/span>
<\/p>\n

\u836f\u7269 ORR \u4e3a 59.5%\u3002<\/span>
<\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u65b0\u6297<\/strong><\/span>\u4f53\u5076\u8054\u836f\u7269\u6cbb\u7597<\/strong><\/span>\u80c3\u764c <\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u540c\u4e00\u5929\uff0cLancet Oncol \u8fd8\u516c\u5e03\u4e86 Trastuzumab deruxtecan \u6cbb\u7597\u8fdb\u5c55\u671f HER2 \u9633\u6027\u80c3\u764c\u7684\u5242\u91cf\u6269\u589e 1 \u671f\u7814\u7a76\u6570\u636e[5]<\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u540c\u6837\uff0c\u836f\u7269\u7684 3 \u7ea7\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u4e3b\u8981\u4e3a\u8840\u6db2\u5b66\u6bd2\u6027\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u3002ORR \u4e3a 43.2%\uff0c\u652f\u6301\u6b64\u836f\u7269\u5728 HER2 \u9633\u6027\u80c3\u764c\u4e2d\u8fdb\u884c\u8fdb\u4e00\u6b65\u7814\u7a76\u3002<\/p>\n


<\/span><\/p>\n

\n

\u4e00\u5171 <\/span>44 <\/span>\u540d <\/span>HER2 <\/span>\u9633\u6027\u80c3\u764c\u6216\u80c3\u98df\u7ba1\u7ed3\u5408\u90e8\u764c\u60a3\u8005\u63a5\u53d7\u6cbb\u7597\u3002<\/span><\/span><\/p>\n


<\/span><\/p>\n

\u6700\u5e38\u89c1\u7684 3 \u7ea7\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u5305\u62ec\u8d2b\u8840\uff0830%\uff09\uff0c\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0820%\uff09\uff0c\u8840\u5c0f\u677f\u51cf\u5c11\uff0818%\uff09\u548c\u767d\u7ec6\u80de\u51cf\u5c11\uff0816%\uff09\u3002\u4e25\u91cd\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u53d1\u751f\u7387 25%\u3002\u53d1\u751f 4 \u4f8b\u80ba\u708e\u3002\u6ca1\u6709\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\u3002<\/span><\/p>\n

ORR <\/span>\u4e3a <\/span>43.2%<\/span>\u3002<\/span>
<\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n

\n
\n
\n
\n


<\/p>\n

\u6dcb\u5df4\u7ed3\u6210\u50cf\u65e0\u76ca\u4e8e\u524d\u54e8\u6dcb\u5df4\u7ed3\u6d3b\u68c0<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

JCO 5 \u6708 1 \u65e5\u516c\u5e03\u63a2\u7d22\u6dcb\u5df4\u7ed3\u6210\u50cf\uff08LSG\uff09\u5bf9\u4e8e\u524d\u54e8\u6dcb\u5df4\u7624\u6d3b\u68c0\uff08SLNB\uff09\u5f71\u54cd\u7684\u524d\u77bb\u6027\u968f\u673a III \u671f SenSzi\uff08GBG80\uff09\u7814\u7a76\u7ed3\u679c[6]<\/span><\/sup>\u3002<\/p>\n


<\/p>\n

\u7814\u7a76\u672a\u80fd\u8bc1\u5b9e LSG \u7684\u5fc5\u8981\u6027\u3002\u65e0\u8bba\u662f\u5426\u884c LSG\uff0cSLNB \u90fd\u4e00\u6837\u6709\u6548\uff0c\u4e14\u4e0d\u884c LSG \u7684 SLNB \u53ef\u4ee5\u52a0\u5feb\u672f\u524d\u5de5\u4f5c\u6d41\u7a0b\uff0c\u964d\u4f4e\u8d39\u7528\u3002<\/p>\n


<\/p>\n

\n

cN0 <\/span>\u65e9\u671f\u4e73\u817a\u764c\u6216\u9ad8\u7ea7\u522b\u5bfc\u7ba1\u539f\u4f4d\u764c\u60a3\u8005\u968f\u673a\uff08<\/span>1:1<\/span>\uff09\u63a5\u53d7\u6709\u6216\u65e0 <\/span>LSG <\/span>\u7684 <\/span>SLNB<\/span>\u3002\u7531\u4e8e <\/span>SLNB <\/span>\u7684\u5047\u9634\u6027\u7387\u548c\u5207\u9664\u7684\u524d\u54e8\u6dcb\u5df4\u7ed3\uff08<\/span>SLNs<\/span>\uff09\u6570\u91cf\u76f8\u5173\uff0c\u9996\u8981\u7814\u7a76\u7ec8\u70b9\u662f\u6bcf\u4f4d\u60a3\u8005\u68c0\u6d4b <\/span>SLNs <\/span>\u7684\u4e2d\u4f4d\u6570\u91cf\u3002<\/span><\/span><\/p>\n


<\/span><\/p>\n

1198 \u540d\u60a3\u8005\u968f\u673a\uff0c\u8fdb\u884c LSG \u548c\u4e0d\u884c LSG \u7684\u4e2d\u4f4d\u68c0\u6d4b SLNs \u6570\u91cf\u662f 2.21 \u548c 2.26\uff0c\u56e0\u6b64\u4e0d\u884c\u672f\u524d LSG \u4e0d\u52a3\u4e8e\u884c LSG \u68c0\u67e5\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n

\n
\n
\n


<\/p>\n

\u76f8\u5173\u6587\u732e\u89c1\u6587\u672b\u3002\u6b22\u8fce\u5927\u5bb6\u7559\u8a00\u5206\u4eab\u6700\u65b0\u8d44\u8baf\u548c\u60f3\u6cd5~<\/span><\/p>\n


<\/p>\n


<\/p>\n

\u7f16\u8f91\uff1adecie | \u8d23\u4efb\u7f16\u8f91\uff1a\u738b\u5f18<\/span><\/p>\n

\u6295\u7a3f\uff1adecie@qq.com<\/span>
<\/p>\n

\u9898\u56fe\uff1a\u7ad9\u9177\u6d77\u6d1bplus<\/span><\/span><\/p>\n


<\/p>\n


<\/p>\n

\u63a8\u8350\u9605\u8bfb\uff1a<\/strong><\/span><\/p>\n

\n

\u80bf\u7624\u514d\u75ab\u9003\u9038\u65b0\u901a\u8def\uff01<\/a><\/p>\n

\u518d\u5582\u517b\u7efc\u5408\u5f81\uff1a<\/span><\/a>\u8425\u517b\u8865\u5145\u4e0d\u80fd\u64cd\u4e4b\u8fc7\u6025<\/span><\/a>
<\/p>\n<\/section>\n

\u4f60\u5e94\u8be5\u77e5\u9053\u7684\u6b63\u786e\u7684\u764c\u75c7\u4f53\u68c0<\/span><\/a><\/h2>\n

\u4e73\u817a\u764c 21 \u57fa\u56e0\u68c0\u6d4b\u7684\u90a3\u4e9b\u4e8b<\/a>
<\/p>\n


<\/p>\n

\"\u80bf\u7624\u5feb\u62a5<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\"\u80bf\u7624\u5feb\u62a5<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\u53c2\u8003\u6587\u732e\uff1a<\/span><\/p>\n

1. Raje N et al. Anti-BCMA CAR T- Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2019May 2<\/span><\/p>\n

2. Nie J et al. Addition of Low-Dose Decitabine to Anti\u2013PD-1 Antibody Camrelizumab in Relapsed\/Refractory Classical Hodgkin Lymphoma. J Clin Oncol 2019 April 30<\/span><\/p>\n

3. Fakhry C et al. Association of Oral HumanPapillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Carcinoma. JAMA Oncol 2019 May 2<\/span><\/p>\n

4. Tamura K et al. Trastuzumab deruxtecan(DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. LancetOncol 2019 April 29<\/span><\/p>\n

5. Shitara K et al. Trastuzumab deruxte can(DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol 2019 April 29<\/span><\/p>\n

6. Kuemmel S et al. Prospective,Multicenter, Randomized Phase III Trial Evaluating the Impact ofLymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer:SenSzi (GBG80) Trial. J Clin Oncol 2019 May 1<\/span><\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

\u80bf\u7624\u65f6\u95f4\u8fd1\u671f\u5feb\u62a5\uff0c\u5e26\u7ed9\u4f60\u6700\u65b0\u7684\u8d44\u8baf\u3002 \u9776\u5411\u9aa8\u9ad3\u7624\uff0cCAR T \u663e\u795e\u529b \u4e34\u5e8a\u524d\u7814\u7a76\u663e\u793a\u4e00\u79cd\u9776\u5411B\u7ec6\u80de\u6210\u719f\u6297\u539f\uff08B […]<\/p>\n","protected":false},"author":1,"featured_media":99224,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/99223"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=99223"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/99223\/revisions"}],"predecessor-version":[{"id":99228,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/99223\/revisions\/99228"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/99224"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=99223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=99223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=99223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}